Trident Lifeline FY26: Crossing 100 Crore Revenue with Registrations-led Growth

Revenue from Operations for FY26 was 10,607.05 lakh (standalone), as stated in the management commentary and FY22 to FY26 P&L snapshot.

H2FY26 standalone revenue was 5,816.27 lakh versus 3,955.17 lakh in H2FY25, and H2FY26 PAT was 967.56 lakh versus 664.71 lakh, per the H2FY26 P&L snapshot.

FY26 revenue mix by product category is stated as Tablets 67%, Capsules 30%, and Suspensions, Syrups, and Toothpaste or mouthwash or other ointments at 1% each.

The presentation states products are registered in 23 countries and the total countries where products are registered as well as under registration is 46 (as of March 31, 2026).

As of March 31, 2026, the company states 1,091 export market products are registered and 2,534 export market product registrations are in process.

The presentation lists monthly capacities as Tablets 120 million, Capsules 120 million, Dry Powder Bottles 3 million, Ointments 3 million, Liquid Bottles 3 million, and Injectable 10 million.

Management commentary states the outlook for FY27 remains robust.